Abstract CT183: Phase (Ph) I/II study of MBG453± spartalizumab (PDR001) in patients (pts) with advanced malignancies
Year: 2019
Type: conference-abstract
Source: Clinical Trials
Authors: Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach, Toshihiko Doi, Wai Meng David Tai, Patrick Forde, John Sarantopoulos, Philippe L. Bedard, Chia-Chi Lin, Stephen Hodi, Sofie Wilgenhof, Armando Santoro, Catherine Sabatos-Peyton, Tyler Longmire, Kitty Wan, Panagiotis Nikolopoulos, Luigi Manenti, Aung Naing
Institutions: European Institute of Oncology, Leiden University Medical Center, University Hospital of Geneva, National Cancer Center Hospital East, National Cancer Centre Singapore, Johns Hopkins University, Johns Hopkins Medicine, Sidney Kimmel Comprehensive Cancer Center, The University of Texas at San Antonio Health Science Center, Mays Cancer Center at UT Health San Antonio, Princess Margaret Cancer Centre, National Taiwan University Hospital, Dana-Farber Cancer Institute, The Netherlands Cancer Institute, Novartis (Switzerland), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4253739332